A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes

Completed · Phase 3

Conditions studied: Pre-diabetes

In brief

This is an exploratory study to assess whether vildagliptin, an unapproved drug, can increase insulin secretion in subjects with pre-diabetes who have a defect in the insulin response and elevated levels of fasting glucose.

Key facts

Study ID

NCT00312130

Run by

Novartis

People needed

20

Starts

2005-04-01

Expected to finish

2006-11-01

Last updated by the study team

2016-11-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• BMI in the range 22-45 and with a stable weight for the last 6 months
• Blood glucose criteria must be met
• Written informed consent

You may not qualify if…

• Pregnancy or lactation
• Previous diagnosis of type 2 diabetes or treatment with hypoglycemic agents
• Type 1 diabetes
• Evidence of cardiovascular complications as defined by the protocol
• Evidence of diabetic complications as defined by the protocol

Where it is running

• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.